Novartis drug fail

Novartis Twin Drug Setbacks Pile Pressure on Pipeline and CEO

Novartis shares fell nearly 9% after a failed late-stage trial for its muscle-wasting disorder drug, the second major pipeline setback this year. The failure pressures CEO Vas Narasimhan's acquisition